The cloning and characterization of the AT111 gene and its complementary deoxyribonucleic acids (cDNA) have now made possible a detailedanalysis and a more comprehensive understanding of the molecular basis of AT111 deficiencies [7- 101. Of central importance to this process has been the identification of restriction fragment length polymorphisms (RFLPs) that have allowed for the separation of parental alleles and for the ability to establish which of two alleles in affected persons is the mutated one. Two such RFLPs have been identified. One results from a silent nucleoticle change in exon IV of the coding region of the gene that either preserves or destroys a PstI restriction enzyme site [ 111. The second results from an insertion/deletion in the 5'-flanking region [121 (Figure 1) . When genomic DNA is digested with the restriction enzyme PstI and subjected to Southern blotting using a fulllength cDNA probe, these different alleles can be resolved [11, 13] . They have been referred to as (+) or (-) to connote the presence or absence of the PstI site in exon IV and as fast or slow to indicate the size clifferences in the 5'-flanking region PstI fragments. September 11, 1989 The American Journal of Medicine Volume 87 (suppl 38) 3c15s
A ntithrombin III (ATIII) deficiency can be divided into two general categories, acquired and inherited. The former results from a decrease in the synthesis of AT111 such as occurs in aclvancecl hepatic disease. It may also result from an increased loss of AT111 as seen in the protein-losing enteropathies and nephropathies.
Inherited AT111 deficiency, on the other hand, has a familial basis and demonstrates a classic menclelian mode of autosomal-dominant inheritance [l-33. Its incidence has been estimated at as low as 1:2,000 to 1:5,000 in the general population, although more recent studies have indicated it to be somewhat less common [4] . Nevertheless, it probably represents one of the more prevalent forms of congenital coagulopathies.
Inherited AT111 deficiency has classically been divided into two basic types: type I, in which both antigenie levels and functional activity of AT111 are proportionately reduced, and type II, in which normal or near-normal antigen levels are found in association with dysfunctional AT111 activity 121. The former type probably accounts for 80 to 90 percent of inherited cleficiencies and is associated with a remarkably homogeneous 50 to 70 percent reduction in plasma AT111 levels in the affected persons. Type II deficiencies were originally discovered after observing abnormal progressive AT111 or heparin cofactor activities despite what appeared to be normal plasma AT111 antigen levels [5, 6] . We now appreciate that the type I de& ciencies probably result from genetic mutations that produce silent ATIII alleles, whereas type II deficiencies result from point mutations in the AT111 protein that cause abnormal thrombin or heparin binding. The presence of these two frequent polymorphisms in the AT111 gene has permitted identification of the mutant alleles in nearly all affected kindreds. For example, in a recent collaborative study, we have been successful in this regard in 15 or 16 cases 1131. Our results can be summarized as follows: (1) all affected persons appear by Southern blot analysis to have two normal-appearing AT111 genes, so the mutations that cripple the affected allele do not involve large DNA rearrangements, insertions, or deletions; (2) in one case, a total deletion of one AT111 gene was observed, thus accounting for an apparently rare form of the deficiency state.
NORMAL AND ABNORMAL ATM GENES
It should be emphasized that the identification of these two polymorphisms, along with family studies, provides an unequivocal means of determining which of two normal-appearing AT111 alleles is dysfunctional. This has allowed the unambiguous cloning of the correct allele from genomic libraries in order to explore the basis for some of the type II deficiencies described below.
In the simplest case, the AT111 molecule can be viewed as being composed of two functional domains, one encoding heparin binding and centered. around the Arg,, residue, and the other encoding the serine protease inhibitor (thrombin-binding) domain centered around Arg,,,Ser,,,.
A combination of classic protein sequencing and contemporary molecule genetic techniques has been employed to examine the basis for several of the known type II AT111 deficiencies. In all cases so far examined, single amino acid substitutions account for the observed effects on heparin or thrombin binding. Figure 2 summarizes the mutants that have so far been characterized.
A MOLECULAR CLASSIFICATION OF ATIll DEFICIENCIES
Careful correlations between AT111 antigen levels, functional activities, and specific mutations in the AT111 protein have now demonstrated that the classic division of inherited AT111 deficiencies into only two types is probably oversimplified.
For example, Bock et a.1 1141 have sequenced the entire AT111 Utah cocling region and have shown that the only mutation is one that alters the normal Pro.l,,T to Leu 1141. Yet, persons with this mutation have consistently low AT111 levels [15] . This is clearly not a classic type II cleficiency in which antigen levels are unaffected. Rather, either the single nucleoticle substitution reduces the rate of messenger ribonucleic acid transcription or translation, or the mutant protein has a reduced plasma half-life. We have proposed a more refined classification scheme that takes into account these clifferences and that can be correlated with specific AT111 mutations (Table I) [lG]. We suggest that type I deficiencies arise as a result of what is probably a heterogeneous group of disorders not unlike those causing the beta-thalassemias.
These would include frame shift and nonsense mutations as well as those affecting splice junctions, promoters, and enhancers in and around the actual structural gene. In rare cases, larger deletions or rearrangements might account for the loss of gene function. Unlinked mutations might affect genes whose products are concerned with maintaining normal AT111 messenger ribonucleic acid or protein levels, although such mutations have not been described. l)pe II deficiencies are of a qualitative nature in which AT111 levels and heparin binding are within the normal range but thrombin binding is defective. ATIIIs Denver and Hamilton are examples [17, 18] . Other variants of this type include ATIIIs Northwick Park, Trenton, and Milan0 (Figure 2 ) [19] .
Type IIIA deficiencies alter the heparin-binding domain and result in diminished cofactor activity while leaving progressive AT111 activity unaffected. ATIIIs Toyama, Tours, and Rouen I and II are within this group [20X3] .
Type IIIB deficiencies also affect the heparin-bincling domain but actually result in increased heparin binding. This has been described for AT111 Chicago, although the exact molecular defect has not been elucidated.
Type IV deficiencies are exemplified by AT111 Utah, where a single mutation accounts for a recluction in antigen level as well as for reduced thrombinbinding capacity [ 141.
Class V deficiencies are similar in nature to type IVs in that quantitative ancl qualitative defects exist simultaneously. However, in this class, heparin-binding activity is reduced, whereas thrombin binding is normal. ATIIIs Base1 and Roma are cases in point 124,251, although in the latter case, the exact molecular defect has not been determined.
CONCLUSIONS AND PROSPECTS FOR THE FUTURE
Clearly, the past five years have seen remarkable progress in our understanding of inherited AT111 deficiency. Particularly useful has been the cataloging of the individual point mutations that contribute to the various qualitative disorders illustratecl in Figure 2 , Rome, Base1 I. 1 = decreased: t = Increased; NL = normal levels. *In class IV mutabons. antigen levels and hepann bindmg are reduced ptoportionalty. Thrombrn brndmg IS reduced even more, owrng to an alteration of the binding sue. Thrs feature drshngurshes thus class from the type I mutations In whtch antigen levels, hepann brndmg and ihrombm bmdrng are all reduced proportronally. Tin class V mutations, anbgen levels and thrombm bmding are reduced proportionately. Hepann bmdrnn IS reduced even further, presumably because of a pomt mutahon rn or near the N-termmal hepann-bmdmg domam.
SYMPOSIUM ON ANTITHROMBIN Ill I PROCHOWNIK as they now allow us to estimate the minimal functional sizes of the heparin-and thrombin-binding clomains. It can be predicted that new techniques such as the polymerase chain reaction 1261 and direct genomic sequencing will enable workers to quickly and easily compile many additional naturally occurring mutants without resorting to long and laborious protein sequencing or molecular cloning techniques. High-efficiency oligonucleoticle-directed mutagenesis [27] coupled with in. uitro and/or i?z uivo expression [28] will permit the generation of multiple individual point mutations and determination as to how they affect various aspects of AT111 structure and function. On the clinical front, it might be expected that similar approaches will allow the production of recombinant AT111 molecules with extended i?z viva half-lives that might serve as a form of second-generation replacement therapy in persons at high risk for the complications associated with inherited AT111 deficiency.
